REG - Assura plc - Dividend Declaration

AssuraAnnouncement

01/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221201:nRSA1738Ia&default-theme=true

RNS Number : 1738I  Assura PLC  01 December 2022

 

1 December 2022

Assura plc

 

Notice of Dividend

 

Assura plc ("Assura" or "the Company"), the UK's leading primary care property
investor and developer, today announces that the next quarterly interim
dividend of 0.78 pence per share will be paid on 11 January 2023 to
shareholders on the register on 9 December 2022 (the "Record Date"). The
Ex-dividend Date will be 8 December 2022.

 

This interim dividend will be a normal dividend (non-PID). Please refer to
Company's website HERE
(https://www.assuraplc.com/investor-relations/shareholder-information/reit-dividends-and-uk-tax)
for more information.

 

Shareholders may choose for the dividend to be paid either as cash or to be
settled in New Shares via the Scrip Dividend Alternative. The Scrip Dividend
Alternative price is to be calculated using the average of the middle market
quotations for an Ordinary Share, as derived from the Daily Official List of
the London Stock Exchange, for the five consecutive business days commencing
on the Ex-dividend Date and will be announced by the Company and detailed on
the Company's website on 15 December 2022.

 

Any shareholders wishing to take up the Scrip Dividend Alternative, who have
not already done so, will have until 4.30pm on 29 December 2022 either to
return their completed mandate form to the Company registrars, Link Group at
10(th) Floor, Central Square, 29 Wellington Street, Leeds, LS1 4DL (in the
case of shareholdings in certificated form) or to take the necessary action
via the CREST system (in the case of shareholdings in uncertificated form).

 

The Circular concerning this Scrip Dividend Alternative is available on the
Company's website, www.assuraplc.com (http://www.assuraplc.com) and is also
available for inspection at the National Storage
Mechanism https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

- Ends -

 

For more information, please contact:

 

 Assura plc                                   Tel: 01925 945354
 Orla Ball, Company Secretary                 Email: Investor@assura.co.uk
 David Purcell, Investor Relations Director

 FGS Global                                   Tel: 0207 251 3801

                                            Email: Assura@fgsglobal.com
 Gordon Simpson

James Thompson

 

 

 Notes to Editors

Assura plc is a national healthcare premises specialist and UK REIT based in
Warrington, UK - caring for more than 600 primary healthcare buildings, from
which almost seven million patients are served.

 

A constituent of the FTSE 250 and the EPRA* indices, as at 30 September 2022,
Assura's portfolio was valued at £2,879 million.

 

At Assura, we BUILD for health. Assura builds better spaces for people and
places, invests in skills and inspires new ways of working, and unlocks the
power of design and innovation to deliver lasting impact for communities -
aiming for six million people to have benefitted from improvements to and
through its healthcare buildings by 2026.

 

Assura is leading for a sustainable future, targeting net zero carbon across
its portfolio by 2040.

 

Further information is available at www.assuraplc.com
(http://www.assuraplc.com)

 

*EPRA is a registered trademark of the European Public Real Estate
Association.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DIVBMBBTMTBJTJT